Sarilumab Beneficial for Polymyalgia Rheumatica Patients
THURSDAY, Oct. 5, 2023 (HealthDay News) -- For patients with polymyalgia rheumatica with relapse during tapering of glucocorticoid therapy, treatment with sarilumab, the human monoclonal antibody that binds to the interleukin-6 receptor α, is efficacious for achieving sustained remission and reducing cumulative glucocorticoid dose, according to a study published in the Oct. 5 issue of the New England Journal of Medicine.
Robert F. Spiera, M.D., from Weill Cornell Medical College in New York City, and colleagues conducted a phase 3 trial in which patients were randomly assigned to receive 52 weeks of a twice-monthly subcutaneous injection of either sarilumab or placebo plus a 14-week prednisone taper (60 and 58 patients, respectively). The primary outcome was sustained remission at 52 weeks.
The researchers found that at week 52, sustained remission occurred in 28 and 10 percent of patients in the sarilumab and placebo groups, respectively. At 52 weeks, the median glucocorticoid dose was significantly lower in the sarilumab group versus placebo group (777 versus 2,044 mg, respectively). Neutropenia, arthralgia, and diarrhea were the most common adverse events with sarilumab versus placebo (15 versus 0 percent; 15 versus 5 percent; and 12 versus 2 percent, respectively). Compared with the placebo group, the sarilumab group reported more treatment-related discontinuations (12 versus 7 percent).
"These findings indicate a glucocorticoid-sparing and remission-maintenance effect of sarilumab," the authors write.
The study was funded by Sanofi and Regeneron Pharmaceuticals, which manufacture sarilumab.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Related Posts
Hay señales de que un fármaco experimental podría frenar una forma de ELA
VIERNES, 23 de septiembre de 2022 (HealthDay News) -- Las personas con una rara...
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician's Briefing chose as the most important...
Do You Live in a ‘Hot Spot’ for Diabetes Complications?
MONDAY, June 13, 2022 (HealthDay News) -- Texas and Florida are big U.S. centers...
Los partos inducidos podrían ayudar a prevenir una importante complicación del embarazo
LUNES, 10 de abril de 2023 (HealthDay News) -- Una complicación potencialmente...